Your browser doesn't support javascript.
loading
Tumor volumes in T3 supraglottic cancers treated with radiotherapy in the modern era: A study of the Canadian Head & Neck Collaborative Research Initiative.
Malik, Nauman H; Fu, Rui; Hainc, Nicolin; Noel, Christopher W; de Almeida, John R; Hosni, Ali; Huang, Shao Hui; Yu, Eugene; Dzioba, Agnieszka; Leung, Andrew; Mangat, Arvindpaul; MacNeil, Danielle; Nichols, Anthony C; Hiremath, Shivaprakash B; Chakraborty, Santanu; Jooya, Alborz; Gaudet, Marc; Johnson-Obaseki, Stephanie; Whelan, Jonathan; Forghani, Reza; Hier, Michael P; Morand, Grégoire; Sultanem, Khalil; Dort, Joseph; Lysack, John; Matthews, Wayne; Nakoneshny, Steven; Gill, Gia; Globerman, Adam; Kerr, Paul; Maralani, Pejman; Karam, Irene; Eskander, Antoine.
Afiliação
  • Malik NH; Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
  • Fu R; Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
  • Hainc N; Department of Otolaryngology-Head and Neck Surgery, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Noel CW; Department of Neuroradiology, Clinical Neuroscience Center, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • de Almeida JR; Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada.
  • Hosni A; Department of Otolaryngology-Head and Neck Surgery, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Huang SH; Department of Otolaryngology-Head and Neck Surgery, Princess Margaret Cancer Centre-University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Yu E; Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
  • Dzioba A; Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
  • Leung A; Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada.
  • Mangat A; Department of Otolaryngology-Head and Neck Surgery and Oncology, London Health Sciences Center, London, Ontario, Canada.
  • MacNeil D; Department of Radiology, Department of Medical Imaging, Western University, London, Ontario, Canada.
  • Nichols AC; Department of Radiology, Department of Medical Imaging, Western University, London, Ontario, Canada.
  • Hiremath SB; Department of Otolaryngology-Head and Neck Surgery and Oncology, London Health Sciences Center, London, Ontario, Canada.
  • Chakraborty S; Department of Otolaryngology-Head and Neck Surgery and Oncology, London Health Sciences Center, London, Ontario, Canada.
  • Jooya A; Department of Radiology, Division of Neuroradiology, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • Gaudet M; Department of Radiology, Division of Neuroradiology, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • Johnson-Obaseki S; Division of Radiation Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.
  • Whelan J; Division of Radiation Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.
  • Forghani R; Department of Otolaryngology-Head & Neck Surgery, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.
  • Hier MP; Department of Otolaryngology-Head & Neck Surgery, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.
  • Morand G; Department of Otolaryngology Head and Neck Surgery, McGill University, Jewish General Hospital, Montreal, Québec, Canada.
  • Sultanem K; Department of Radiology, University of Florida College of Medicine, Gainesville, Florida, USA.
  • Dort J; Department of Otolaryngology Head and Neck Surgery, McGill University, Jewish General Hospital, Montreal, Québec, Canada.
  • Lysack J; Department of Otolaryngology Head and Neck Surgery, McGill University, Jewish General Hospital, Montreal, Québec, Canada.
  • Matthews W; Department of Oncology, McGill University, Jewish General Hospital, Montréal, Québec, Canada.
  • Nakoneshny S; Division of Otolaryngology-Head and Neck Surgery, University of Calgary, Calgary, Alberta, Canada.
  • Gill G; Section of Neuroradiology, Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Globerman A; Division of Otolaryngology-Head and Neck Surgery, University of Calgary, Calgary, Alberta, Canada.
  • Kerr P; Division of Otolaryngology-Head and Neck Surgery, University of Calgary, Calgary, Alberta, Canada.
  • Maralani P; Department of Otolaryngology-Head & Neck Surgery, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Karam I; Department of Radiology, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Eskander A; Department of Otolaryngology-Head & Neck Surgery, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Head Neck ; 46(3): 561-570, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38116716
ABSTRACT

PURPOSE:

To evaluate the association of primary tumor volume (TV) with overall survival (OS) and disease-free survival (DFS) in T3 N0-3M0 supraglottic cancers treated with intensity-modulated radiotherapy (IMRT).

METHODS:

This was a retrospective cohort study involving 239 patients diagnosed with T3 N0-3M0 supraglottic cancers between 2002 and 2018 from seven regional cancer centers in Canada. Clinical data were obtained from the patient records. Supraglottic TV was measured by neuroradiologists on diagnostic imaging. Kaplan-Meier method was used for survival probabilities, and a restricted cubic spline Cox proportional hazards regression analysis was used to analyze TV associations with OS and DFS.

RESULTS:

Mean (SD) of participants was 65.2 (9.4) years; 176 (73.6%) participants were male. 90 (38%) were N0, and 151 (64%) received concurrent systemic therapy. Mean TV (SD) was 11.37 (12.11) cm3 . With mean follow up (SD) of 3.28 (2.60) years, 2-year OS was 72.7% (95% CI 66.9%-78.9%) and DFS was 53.6% (47.4%-60.6%). Increasing TV was associated (per cm3 increase) with worse OS (HR, 1.01, 95% CI 1.00-1.02, p < 0.01) and DFS (HR, 1.01, 95% CI 1.00-1.02, p = 0.02).

CONCLUSIONS:

Increasing primary tumor volume is associated with worse OS and DFS in T3 supraglottic cancers treated with IMRT, with no clear threshold. The findings suggest that patients with larger tumors and poor baseline laryngeal function may benefit from upfront laryngectomy with adjuvant radiotherapy.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Neoplasias Laríngeas Limite: Female / Humans / Male País/Região como assunto: America do norte Idioma: En Revista: Head Neck Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Neoplasias Laríngeas Limite: Female / Humans / Male País/Região como assunto: America do norte Idioma: En Revista: Head Neck Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá